drugset / Trial / NCT05953012
Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1 study, first-in-human (FIH), open label study to evaluate the safety, tolerability and identify the maximum tolerated dose (MTD) of PMC-403 and determine the recommended phase 2 dose (RP2D).
Timeline
- Start
- 2023-07-20
- Primary completion
- 2025-08-22
- Completion
- 2025-12-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PMC-403 | Unknown | 0.7 mg | Intravitreal |
| Subject | PMC-403 | Unknown | 2 mg | Intravitreal |
| Subject | PMC-403 | Unknown | 3 mg | Intravitreal |
| Subject | PMC-403 | Unknown | 4 mg | Intravitreal |